krazati - adagrasib tablet, coated
(Adagrasib)Mirati Therapeutics, Inc
Usage: Krazati (adagrasib) treats KRAS G12C-mutated locally advanced or metastatic NSCLC (as a single agent, after prior therapy) and metastatic colorectal cancer (combined with cetuximab, after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy) in adults.